ReachRxResearch
Home
Research
Sign Up
KDOQI Commentary on the 2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
Back to Research Hub
  1. Home
  2. Research Hub
  3. KDOQI Commentary on the 2025 AHA/ACC Gui…

KDOQI Commentary on the 2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

American Journal of Kidney Diseases·October 21
Urology & NephrologyPractice changingChronic Kidney DiseaseHypertensionExpert Commentary / Guideline ReviewAntihypertensive TherapyAdult

Summary

View source

What was studied

A KDOQI expert work group reviewed and commented on the 2025 AHA/ACC Guideline for hypertension management, focusing on implications for adults with non-dialysis-dependent CKD (stages 1–5), including areas where the guideline does not offer formal recommendations (e.g., medication interactions, electrolyte imbalances, kidney injury).

Key findings

The KDOQI work group broadly supports the 2025 AHA/ACC recommendations, including the <130/80 mm Hg blood pressure target and the adoption of the PREVENT calculator (which integrates cardiovascular, kidney, and metabolic parameters), while identifying gaps and additional considerations specific to CKD management.

Study limitations

This is an expert commentary rather than an original study, so conclusions reflect consensus opinion rather than new primary evidence. The commentary explicitly excludes patients on maintenance dialysis, limiting applicability to that population.

Clinical implications

Clinicians managing CKD patients should apply the <130/80 mm Hg blood pressure target and use the PREVENT risk calculator, which now incorporates kidney health parameters. Pay special attention to CKD-specific concerns such as medication interactions, electrolyte imbalances, and acute kidney injury risk not fully addressed in the AHA/ACC guideline itself.

Caveats

  • Findings apply only to non-dialysis-dependent CKD (stages 1–5); patients on maintenance dialysis are explicitly excluded
  • The 2025 AHA/ACC guideline itself is the primary source of recommendations; this commentary adds CKD-specific context and identifies evidence gaps rather than generating new evidence
  • This is a guideline commentary, not a primary study — recommendations reflect expert opinion and consensus, not new trial data

Related Questions

Explore related topics

What blood pressure targets are recommended for patients with CKD stages 3-5?How does the PREVENT cardiovascular risk calculator incorporate kidney disease?Management of resistant hypertension in chronic kidney disease

Publication Details

Year
2026
Journal
American Journal of Kidney Diseases
Source
View article
Keep scrolling
More content below.
Up Next